{{expand|time=2017-12-24T17:32:48+00:00}}
{{medical}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443663022
| IUPAC_name = 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[5,4-c]pyridine-3-carboxamide
| image = apixaban.svg

<!--Clinical data-->
| tradename = Eliquis
| Drugs.com = {{Drugs.com|parent|eliquis}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = B
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = Oral
| licence_EU        = Eliquis
| licence_US        = Apixaban

<!--Pharmacokinetic data-->
| bioavailability = ca. 50%
| protein_bound =  
| metabolism =  
| elimination_half-life = 9–14 h
| excretion = 75% [[biliar|biliar]]y, 25% [[renal|renal]]ly

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 503612-47-3
| ATC_prefix = B01
| ATC_suffix = AF02
| PubChem = 10182969
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB07828
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 72296
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8358471
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3Z9Y7UWC1J
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03213
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 231779
| synonyms = BMS-562247-01

<!--Chemical data-->
| C=25 | H=25 | N=5 | O=4 
| molecular_weight = 459.497 g/mol
| smiles = O=C5N(c4ccc(N3C(=O)c1c(c(nn1c2ccc(OC)cc2)C(=O)N)CC3)cc4)CCCC5
| InChI = 1/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
| InChIKey = QNZCBYKSOIHPEH-UHFFFAOYAJ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = QNZCBYKSOIHPEH-UHFFFAOYSA-N
}}
'''阿哌沙班'''（通用名：Apixaban，INN，商品名：Eliquis）是一种用于预防静脉[[血栓栓塞|血栓栓塞]](thromboembolism)和[[房颤|房颤]][[中风|中风]]的抗凝血剂。它是一种[[直接Xa因子抑制剂|直接Xa因子抑制剂]](direct factor Xa inhibitor)。自2011年5月阿哌沙班已在欧洲上市。该药由[[辉瑞|辉瑞]]和[[百时美施贵宝|百时美施贵宝]]的合资企业开发。

Apixaban可用於心房顫動之急性冠狀動脈症候群(ACS)以及經皮冠狀動脈介入治療(PCI)患者之抗血栓治療。臨床試驗證實Apixaban在心房顫動患者建議劑量下的安全性和有效性。包含Apixaban在內的新型口服抗凝血劑合併P2Y12抑制劑，為目前North American guidance對於預防有心房顫動之ACS或PCI的患者中風及系統性栓塞的建議用藥。<ref>{{cite journal |author1=6. R. D. Lopes, G. Heizer, R. Aronson, A. N. Vora, T. Massaro, R. Mehran,S. G. Goodman, S. Windecker, H. Dariu, J. Li, O. Averkov, M. C. Bahit, O. Berwanger,A. Budaj,Z. Hijazi, A. Parkhomenko, P. Sinnaeve, R. F. Storey,H. Thiele, D. Vinereanu, C. B. Granger and J. H. Alexander |title=Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation |journal=The new england journal of medicine |date=2019 |doi=10.1056/NEJMoa1817083}}</ref>
{{抗血栓药}}

[[分类:药物|分类:药物]]